Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 2/20 | 0.60 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | AVPR2 | P30518 | 8/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.46 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.46 |
| ▸ | AVPR1A | P37288 | 3/20 | 0.45 |
| ▸ | OXTR | P30559 | 1/20 | 0.44 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6202811 | 0.81 | BRD4 (0.60) | BRD4CRBNALDH1A1LMNANPSR1 | |
| Hydrochloric Acid SCHEMBL5270039 | 0.81 | AVPR2 (0.56) | AVPR2PDCD1CD274AVPR1AOXTR | |
| SCHEMBL6970210 | 0.80 | BRD4 (0.59) | BRD4CRBNALDH1A1LMNANPSR1 | |
| SCHEMBL2937306 | 0.78 | AVPR2 (0.58) | ALDH1A1AVPR2PDCD1CD274 | |
| SCHEMBL6966461 | 0.78 | BRD4 (0.65) | BRD4CRBNALDH1A1LMNANPSR1 | |
| SCHEMBL1346004 | 0.77 | AVPR2 (0.69) | AVPR2AVPR1AOXTR | |
| SCHEMBL6972632 | 0.77 | BRD4 (0.61) | BRD4CRBNALDH1A1LMNANPSR1 | |
| SCHEMBL20277652 | 0.76 | AVPR1A (0.52) | BRD4ALDH1A1LMNANPSR1AVPR2 | |
| Hydrochloric Acid SCHEMBL4195564 | 0.76 | AVPR2 (0.68) | AVPR2AVPR1AOXTR | |
| Hydrochloric Acid SCHEMBL5552018 | 0.76 | PDCD1 (0.47) | AVPR2PDCD1CD274AVPR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1399436-B1 | OXYTOCIN AGONISTS | FERRING BV (NL) | 2005-03-16 | — | — | EP | disclosed |
| US-20040235753-A1 | Oxytocin agonists | PITT GRAY ROBERT WILLIAM (GB) | 2004-11-25 | — | — | US | disclosed |
| EP-1399436-A2 | OXYTOCIN AGONISTS | Ferring BV (NL) | 2004-03-24 | — | — | EP | disclosed |
| WO-2003000692-A2 | OXYTOCIN AGONISTS | FERRING BV (NL) | 2003-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235753-A1 | Oxytocin agonists | OXTR, GNRHR, PRLHR | BRD4 3590/4885CRBN 3797/4885ALDH1A1 3533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.